Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $198 | 6-8 weeks | |
5 mg | $347 | 6-8 weeks | |
25 mg | $1,140 | 6-8 weeks | |
50 mg | $1,490 | 6-8 weeks | |
100 mg | $1,990 | 6-8 weeks | |
1 mL x 10 mM (in DMSO) | $382 | 6-8 weeks |
Description | Seviteronel racemate is the racemate form of Seviteronel and is a potent inhibitor of CYP17 lyase. |
Targets&IC50 | CYP17 Lyase (human):69 nM |
In vivo | The MDA-PCa-133 xenograft, originating from a clinical castration-resistant prostate cancer (CRPC) bone metastasis, exhibits expression of PSA, the full-length androgen receptor (AR), and the AR-V7 isoform subcutaneously. In a study involving castrated male mice bearing the MDA-PCa-133 tumor, subjects were divided into three groups and underwent 25 days of oral treatment with either a vehicle, Seviteronel (VT-464) at 100 mg/kg twice daily, or Abiraterone Acetate (AA) at 100 mg/kg twice daily. Results demonstrated that both Seviteronel (VT-464) and AA significantly reduced tumor volume by more than two-fold relative to the vehicle group (p<0.05). The study highlights that Seviteronel’s (VT-464) selective CYP17 lyase inhibition is comparably effective to AA’s CYP17 inhibition in reducing tumor volume in this model [2]. |
Alias | VT-464 (racemate) |
Molecular Weight | 399.34 |
Formula | C18H17F4N3O3 |
Cas No. | 1375603-36-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (125.21 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.